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Purpose: Diabetes mellitus causes both macrovascular and
microvascular complications. Several treatments effectively prevent
macrovascular complications such as stroke and AMI. Because current
treatments are insufﬁcient to prevent diabetic microvascular complica-
tions such as diabetic retinopathy and nephropathy, erectile dysfunction
and cardiomyopathy, we aimed to study a possibility of endothelin
antagonism on these microvascular complications. Vascular endothelial
growth factor (VEGF) was reported to cause a central trigger leading to
the structural and functional changes in diabetic complications, and we
also assessed restoration of VEGF signaling by endothelin antagonism.
Since both ET-A and ET-B receptors in vascular smooth muscles are
involved in the microvascular contraction/proliferation, we applied the
ET-A/B dual antagonist SB209670 to rats. Methods: Male Sprague–
Dawley ratswere administered citrate saline (vehicle) or streptozotocxin
(65 mg/kg IP). One week after injection, rats were separated into those
receiving SB209670 or vehicle by osmotic mini pump for 2 weeks.
Results: We found reduction of VEGF signaling with capillary density in
diabetic heart and penile tissues, whereas found overexpression of VEGF
signaling in diabetic retina and kidney. SB209670 administration was
effective in preventing development and progression of various diabetic
complications through modiﬁcation of respective microcirculation and
restoration of VEGF signaling; SB209670 prevents diabetic cardiomyop-
athy through restoration of VEGF reduction, prevents erectile dysfunction
through restoration of VEGF reduction, and prevents the development
of diabetic retinopathy and nephropathy through restoration of VEGF
overexpression. Conclusion: Dual endothelin antagonism by SB209670 is
effective in preventing various diabeticmicrovascular complications such
diabetic retinopathy and nephropathy, erectile dysfunction and cardio-
myopathy through both improving organ microcirculation and the
restoration of altered VEGF signaling.
doi:10.1016/j.lfs.2014.01.041
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Background: Increase in central bloodpressure (cBP) is a risk factor for
cardiovascular disease. cBP is higher in the obese individuals than the age-
matched normal-weight humans. We previously demonstrated that
lifestyle modiﬁcation decreases cBP in obese men. However, the
mechanism underlying lifestyle modiﬁcation-induced decrease in cBP
has not been elucidated. Testosterone is a kind of androgens and known
to have cardioprotective effect. The aim of the present study was to
examine whether testosterone is involved in the mechanism underlying
the decrease in cBP with lifestyle modiﬁcation. Methods: Thirteen over-
weight and obesemen (age: 50 ± 2 yrs, BMI: 30 ± 1 kg/m2) completed a
12-week lifestyle modiﬁcation program (well-balanced 1680 kcal/day
diet and brisk walking for 40–60 min/day, 3 days/week). Before and after
the program, we measured cBP and serum testosterone level in all
participants. Results: After the program, a signiﬁcant weight loss was
observed (−12.7 ± 1.3 kg, P b 0.05). cBP signiﬁcantly decreased and
serum testosterone level signiﬁcantly increased after the program (both
P b 0.05). Moreover, there was a signiﬁcant relationship between the
change in cBP and that in serum testosterone level (r =−0.63, P b 0.05).
Conclusions: After the 12-week lifestyle modiﬁcation, cBP decreased and
serum testosterone level increased in the overweight and obesemen.We
also demonstrated that there was a negative relationship between the
change in cBP and that in serum testosterone level. Theseﬁndings suggest
that increased serum testosterone level may partly contribute to the
decrease in central blood pressure in overweight and obese men.
doi:10.1016/j.lfs.2014.01.042
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Glucagon-like peptide 1 (GLP-1) is an insulin secretagogue synthe-
sized in the intestine and released in response to meal ingestion and
efﬁciently lowers blood glucose in type 2 diabetic patients. GLP-1(7-36)
has a very short half-life and is rapidly metabolized by dipeptidyl
peptidase IV to the major metabolite GLP-1(9-36)-amide, often thought
to be inactive. Inhibitors of this enzyme arewidely used to treat diabetes.
However, it is unclear whether GLP-1(9-36) mediates functional activity
via speciﬁc receptors. Following pre-incubation of fresh frozen section of
cryostat sections (Bregma ~−2.5) from adult mouse brains, binding
assays were carried out using increasing concentration of either [125I]
GLP-1(7-36) or [125I]GLP-1(9-36) for 90 min at room temperature. Non-
speciﬁc binding was deﬁned by 10 μM of the GLP-1(7-36) and GLP-1(9-
36). In functional experiments, mouse aortae were mounted in wire
myographs and the effect of increasing concentrations of each peptide
was measured.
In the mouse brain both labeled peptides bound with a single high
sub-nanomolar afﬁnity, with Hill slopes close to unity. The density of
receptors was an order of magnitude lower for [125I]GLP-1(9-36). In
functional experiments bothpeptides had similar potencies. These results
suggest that GLP-1(9-36) has functional activity at the GLP1 receptor.
doi:10.1016/j.lfs.2014.01.043
Ligand binding
(mouse brain, n = 4)
KD (nM) BMAX (fmol/mg) nH
[125I]GLP-1(7-36) 1.29 ± 0.26 57.0 ± 14.5 0.96 ± 0.06
[125I]GLP-1(9-36) 0.214 ± 0.08 2.69 ± 0.74 1.06 ± 0.05
Vasoconstrictor Assay
(mouse aorta, n = 3)
pD2 EMAX
(nM) % KCl maximum
GLP-1(7-36) 7.69 ± 0.24 35 ± 8% –
GLP-1(9-36) 7.57 ± 0.64 25 ± 7% –
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